Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
Tendex Issues Voluntary Nationwide Recall of P-Boost, NatuRECT Due to Undeclared Active Ingredients
FOR IMMEDIATE RELEASE - November 19, 2013 - Los Angeles, CA Tendex is voluntarily recalling Lot# F51Q of P-Boost and Lot # F51Q of NatuRECT to the consumer level. FDA laboratory analysis on Lot# F51Q of P-Boost, which the firm also labels as NatuRECT, has determined that this product contains undeclared tadalafil. Tadalafil is an active ingredient of FDA-approved drugs used to treat erectile dysfunction (ED), making these products unapproved drugs.
The undeclared active ingredient poses a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to unsafe levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. To date, there have been no reported adverse events related to this recall.
These products are labeled and intended to be used as dietary supplements for sexual enhancement. They are packaged in 1 capsule blister packs and 5, 10, 20, 40 capsule bottles. Both products are distributed nationwide to wholesale and retail customers and via the internet.
Tendex is notifying its distributors and customers by direct mail or email and is arranging for return of all recalled products. Consumers that have product which is being recalled should stop using and return to place of purchase.
Consumers with questions regarding this recall can contact Tendex by phone (800) 984-0341, from Monday to Friday, 9:00AM-5PM PST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Online: http://www.fda.gov/MedWatch/report.htm
- Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: http://www.fda.gov/MedWatch/getforms.htm.
Mail to address on the pre-addressed form.
- Fax: 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Recalled Product Photos Are Also Available on FDA's Flickr Photostream.